Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

Achieving improvements in survival and reducing relapse remains a challenge in acute myelogenous leukemia (AML) patients. This study evaluated the in vitro efficacy of the active form of novel agent sapacitabine, CNDAC, compared to current chemotherapeutic drugs Ara-C and mitoxantrone using two AML...

Full description

Saved in:
Bibliographic Details
Main Authors: Sucheta Jagan, Laura A. Paganessi, Robin R. Frank, Parameswaran Venugopal, Melissa Larson, Kent W. Christopherson
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2012/727683
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items